N
NAVISUS CORP.
NaviFUS completes innovative pilot study investigating FUS and re-radiotherapy combination treatment for recurrent glioblastoma tumors · NaviFUS ...|This is the first clinical trial in the US to use the NaviFUS device, which combines neuronavigation with a mobile, noninvasive focused ...|The NaviFUS® System combines their focused ultrasound technology platform with recurrent glioblastoma multiforme standard care drug Avastin. By ...|NaviFUS (6872) and Bracco, the world's leading brand of ultrasound imaging agents, officially signed a cooperation agreement recently (4/26). Bracco will ...|NaviFUS is the pioneer in Focused Ultrasound. Learn more about us and our vision, history, management team, company milestones and awards.|The NaviFUS® System, the Neuronavigation-guided focused ultrasound system developed by NaviFUS Corp., has completed a Phase II clinical trial in Taiwan for ...|The “NaviFUS Focused Ultrasound System” developed by NaviFUS Corporation recently won Gold at the 2022 Edison Awards – Science & Medical ...|The “NaviFUS® Focused Ultrasound System” is an innovative product that can safely and non-invasively perform FUS therapy in the clinic.|NaviFUS ® – FUS system that uses ultrasound energy to open the BBB and for neuromodulation; the device has already passed preliminary safety testing.|NAVIRFA® Needle Tracking System is a simple and smart optical 3D surgical tracking technology that enhances RFA and MWA procedures with precision.
Country/Area ：Panama
Company Email ：info@navifus.com
Industry ：BeautyHealth & MedicalBusiness ServicesBusiness Services General
Company address ：AV BALBOA Y AQUILOINO DE LA GUARDIA, PANAMA CITY, Panama
Company website ：*****
Company phone ：+886 225860560
Established ：2015
Company Revenue ：$5,051,000
Number of employees ：<25
SIC Code ：87873
NAICS Code ：54541
Main Products ：NaviFUS® Neuronavigator-guided transcranial focused ultrasound systemNAVIRFA® Needle Tracking System
Company News
NaviFUS begins FUS combined with radiotherapy clinical trial for the treatment of terminal primary brain tumors
Aug 4, 2021
TAIPEI, Aug. 3, 2021 /PRNewswire/ -- NaviFUS' focused ultrasound (FUS) therapy system (NaviFUS®) was recently approved for use in a new clinical trial by the Taiwan Food and Drug Administration (TFDA). It will be initiated shortly at Linkou Chang Gung Memorial Hospital. The trial will...
Aug 4, 2021
NaviFUS highlights clinical trial data and device capabilities at virtual International Focused Ultrasound SymposiumNov 24, 2020
TAIPEI, Nov. 24, 2020 /PRNewswire/ -- The 7th International Focused Ultrasound Symposium organized by the U.S. Focused Ultrasound Foundation took place from 11/9 to 11/13 in virtual format this year due to the COVID-19 epidemic. During the 5-day conference, participants presented and...
Nov 24, 2020NaviFUS Launches Neuronavigation-guided Clinical Trial to Open the Blood-Brain-Barrier for Combination FUS-Bevacizumab Therapy in rGBM PatientsSep 11, 2020
TAIPEI, Sept. 11, 2020 /PRNewswire/ -- Genovate Biotech (TPEX:4130) subsidiary and Taiwan-based focused ultrasound (FUS) manufacturer NaviFUS Corporation is pleased to announce the start of its clinical trial (NCT04446416) for the combination of FUS plus bevacizumab therapy. Researchers...
Sep 11, 2020Web Summary
Q1: What is the address of NaviFUS Corp., and where was it founded?
A1: The exact address of NaviFUS Corp. is not explicitly mentioned in the provided content, but according to the company's history, it was founded in Taiwan.
Q2: What products does NaviFUS develop for crossing the blood-brain barrier (BBB) for enhanced oncology drug delivery?
A2: The product developed by NaviFUS is called the NaviFUS System, which utilizes non-invasive ultrasound energy to enable transient and safe enhancement of BBB permeability to facilitate the transport of small or large molecular CNS drugs to target tumor tissue at high precision.
Q3: What industry does NaviFUS Corp. operate in?
A3: NaviFUS Corp. operates in the biotechnology industry, specifically in the field of biomedical devices and pharmaceuticals.
Q4: What services does NaviFUS provide for its customers?
A4: Although not explicitly stated, based on the provided content, it can be inferred that NaviFUS provides a service related to focused ultrasound therapy for treating brain tumors and epilepsy, as well as other CNS diseases.
Q5: Who are the key members of NaviFUS's management team?
A5: The key members of NaviFUS's management team include Jen Chen, Ph.D. (Chairman of the Board), Arthur Lung, Ph.D. (Chief Executive Officer), and Hao-Li Liu, Ph.D. (Founder & Chief Technical Consultant).
Q6: What is the vision of NaviFUS Corp., and how does it aim to benefit patients?
A6: The vision of NaviFUS Corp. is to provide novel platform solutions for crossing the blood-brain barrier (BBB) for enhanced oncology drug delivery, with the goal of benefiting CNS disease patients locally and globally by bringing breakthrough therapeutic ultrasound technology to clinical use.
Q7: What are some notable milestones achieved by NaviFUS Corp., including funding rounds and awards?
A7: Some notable milestones achieved by NaviFUS Corp. include receiving $6M USD in Series A1 funding, winning the 12th National Innovation Award, and securing $7M USD in Series A2 funding.
Q8: What is the current status of NaviFUS's clinical trials, including ongoing and completed trials?
A8: According to the provided content, NaviFUS has conducted or participated in several clinical trials for treating brain tumors and epilepsy, including a Phase 1 safety trial for rGBM-FUS, a Phase 1 Epilepsy clinical trial, and a FUS+bevacizumab clinical trial.
A1: The exact address of NaviFUS Corp. is not explicitly mentioned in the provided content, but according to the company's history, it was founded in Taiwan.
Q2: What products does NaviFUS develop for crossing the blood-brain barrier (BBB) for enhanced oncology drug delivery?
A2: The product developed by NaviFUS is called the NaviFUS System, which utilizes non-invasive ultrasound energy to enable transient and safe enhancement of BBB permeability to facilitate the transport of small or large molecular CNS drugs to target tumor tissue at high precision.
Q3: What industry does NaviFUS Corp. operate in?
A3: NaviFUS Corp. operates in the biotechnology industry, specifically in the field of biomedical devices and pharmaceuticals.
Q4: What services does NaviFUS provide for its customers?
A4: Although not explicitly stated, based on the provided content, it can be inferred that NaviFUS provides a service related to focused ultrasound therapy for treating brain tumors and epilepsy, as well as other CNS diseases.
Q5: Who are the key members of NaviFUS's management team?
A5: The key members of NaviFUS's management team include Jen Chen, Ph.D. (Chairman of the Board), Arthur Lung, Ph.D. (Chief Executive Officer), and Hao-Li Liu, Ph.D. (Founder & Chief Technical Consultant).
Q6: What is the vision of NaviFUS Corp., and how does it aim to benefit patients?
A6: The vision of NaviFUS Corp. is to provide novel platform solutions for crossing the blood-brain barrier (BBB) for enhanced oncology drug delivery, with the goal of benefiting CNS disease patients locally and globally by bringing breakthrough therapeutic ultrasound technology to clinical use.
Q7: What are some notable milestones achieved by NaviFUS Corp., including funding rounds and awards?
A7: Some notable milestones achieved by NaviFUS Corp. include receiving $6M USD in Series A1 funding, winning the 12th National Innovation Award, and securing $7M USD in Series A2 funding.
Q8: What is the current status of NaviFUS's clinical trials, including ongoing and completed trials?
A8: According to the provided content, NaviFUS has conducted or participated in several clinical trials for treating brain tumors and epilepsy, including a Phase 1 safety trial for rGBM-FUS, a Phase 1 Epilepsy clinical trial, and a FUS+bevacizumab clinical trial.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
